We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 43.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$945M 12.01%
20,739,426
+3,500
+0% +$167K
GEVA
2
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$883M 11.23%
10,648,182
+375,000
+4% +$34.7M
PCYC
3
DELISTED
PHARMACYCLICS INC
PCYC
$876M 11.13%
8,737,888
+18,670
+0.2% +$2.43M
INCY icon
4
Incyte
INCY
$25.3B
$794M 10.09%
14,835,559
+25,000
+0.2% +$1.55M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.46B
$498M 6.33%
20,481,442
+526,316
+3% +$13.3M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$360M 4.57%
13,654,150
+3,315
+0% +$95.1K
ITMN
7
DELISTED
INTERMUNE INC
ITMN
$145M 1.84%
4,324,843
+4,174,843
+2,783% +$93M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$128M 1.63%
1,883,230
-58,074
-3% -$4.28M
XOMA
9
DELISTED
Xoma
XOMA
$120M 1.53%
1,152,879
+1,260
+0.1% +$183K
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$84.5M 1.07%
256,375
-106,472
-29% -$35.9M
HALO icon
11
Halozyme
HALO
$9.87B
$72.4M 0.92%
5,698,139
-598,887
-10% -$8.89M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$301M
$72.2M 0.92%
4,445,696
-345,483
-7% -$4.91M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.44B
$62.1M 0.79%
5,867,031
-832,948
-12% -$8.88M
ANAC
14
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$61.9M 0.79%
3,095,318
+595,318
+24% +$11.5M
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$49.3M 0.63%
2,778,654
– –
QCOR
16
DELISTED
QUESTCOR PHARMA INC
QCOR
$46.6M 0.59%
717,745
-58,119
-7% -$3.71M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$45.4M 0.58%
2,380,074
– –
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$44.9M 0.57%
3,537,137
+978,280
+38% +$12.6M
CERS icon
19
Cerus
CERS
$577M
$40.6M 0.52%
8,455,306
– –
GILD icon
20
Gilead Sciences
GILD
$166B
$39.4M 0.5%
556,108
– –
ACOR
21
DELISTED
Acorda Therapeutics
ACOR
$37.9M 0.48%
+8,333
New +$33.7M
CHTP
22
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$37.3M 0.47%
6,760,394
+965,641
+17% +$4.85M
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$36.7M 0.47%
529,990
-748
-0.1% -$54.9K
HRTX icon
24
Heron Therapeutics
HRTX
$92.5M
$30.2M 0.38%
+2,167,784
New +$29M
AEGR
25
DELISTED
Aegerion Pharmaceuticals
AEGR
$23.7M 0.3%
513,922
+13,922
+3% +$816K
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Baker Bros. Advisors held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Acorda Therapeutics worth $37.9M.

  • Baker Bros. Advisors's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Baker Bros. Advisors added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Baker Bros. Advisors's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Baker Bros. Advisors fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Baker Bros. Advisors opened 19 new positions and closed 6 in Q1 2014.
  • Baker Bros. Advisors's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.